In a surprising move, the Trump administration has frozen the leases of several offshore wind farm projects, citing national security concerns. This decision threatens billions in investments and could impact energy reliability along the East Coast.
A newly released FBI report sheds light on the failure to act on Maria Farmer's 1996 allegations against Jeffrey Epstein, revealing how dozens of teen girls suffered in silence for years. The document highlights the dire consequences of inadequate law enforcement responses.
The Trump administration is poised to announce measures effectively banning gender-affirming care for transgender minors, following recent legislative actions. Key health officials will unveil rules impacting Medicaid funding and hospital practices.
In a revealing interview, Susie Wiles shares her experiences working with Trump, leaving Kimmel and Colbert to discuss her insights on his behavior and the inner workings of the White House.
A festive Hanukkah event at Bondi Beach turned tragic as a mass shooting leaves 15 dead and dozens injured. Witnesses describe the chaos and bravery in the face of horror.
A dozen ex-FBI agents are fighting for their jobs back, claiming they were wrongfully terminated for kneeling during protests following George Floyd's death. Their lawsuit alleges political bias and inadequate support from the Justice Department.
The White House faces scrutiny over its military strikes on alleged drug boats off Venezuela. With calls for transparency, the legality of these lethal operations remains in question as death tolls rise.
As the government shutdown drags on, the Trump administration pushes the Supreme Court to freeze full SNAP payments, leaving millions of families struggling for food. Can they survive until a decision is made?
A groundbreaking study reveals that scientists have discovered a method to reprogram the pancreas to produce GLP-1s naturally, eliminating the need for Ozempic and offering new hope for sustainable weight loss.
Despite losing a $10 billion bid for Metsera to Pfizer, Novo Nordisk's CEO Mike Doustdar remains determined to pursue new opportunities in the obesity and diabetes sectors. The company aims to reclaim its position in the booming weight-loss market.